Loading...
Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: updated results from the bexmab phase 1/2 study
Zeidan, A. Stein, A. S. Rimpilainen, J. Pyöräla, M. Siitonen, T. Ball, B. Myllymaki, M. Zeidner, J. Searle, D. E. Witherall, R.
Zeidan, A.
Stein, A. S.
Rimpilainen, J.
Pyöräla, M.
Siitonen, T.
Ball, B.
Myllymaki, M.
Zeidner, J.
Searle, D. E.
Witherall, R.
Abstract
Description
Date
2025
Publisher
Collections
Files
Loading...
Found from Unpaywall
Adobe PDF, 170.64 KB
Keywords
Type
Article
Citation
Zeidan A, Stein AS, Rimpilainen J, Pyöräla M, Siitonen T, Ball B, et al. Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: updated results from the bexmab phase 1/2 study. Blood. 2025 NOV 3;146:236-7.